Literature DB >> 11082812

[Continuous EEG for monitoring on the neurological intensive care unit. New applications and uses for therapeutic decision making].

J Claassen1, T Baeumer, H C Hansen.   

Abstract

Fifteen patients at our neurological intensive care unit were monitored with continuous EEG (cEEG: 10 channels EEG and ECG) for a total of 109 days. Primary indications for monitoring were nonconvulsive seizures in patients with altered consciousness (AC, n = 9) and control of therapy in generalized/partial status epilepticus (SE, n = 5). The cEEG findings influenced therapeutic management of patients in almost 50% of monitoring days (50/109), with decisive decisions (changes in medication) being made in 31/109 days. In 5/9 patients with AC, cEEG revealed findings that could not be demonstrated in previous EEG recordings. Identification of repetitive, nonepileptic, involuntary movements was guided by cEEG in four patients. Aside from the established application of cEEG monitoring in SE, the usefulness of clarifying the differential diagnosis in patients with AC was demonstrated particularly by the finding of nonconvulsive seizures in three patients. In two of these, intermittent EEG recordings did not demonstrate the seizures.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082812     DOI: 10.1007/s001150050669

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  3 in total

1.  Urgent continuous EEG (cEEG) monitoring leads to changes in treatment in half of cases.

Authors:  Lawrence J Hirsch
Journal:  Epilepsy Curr       Date:  2010-07       Impact factor: 7.500

Review 2.  Continuous electroencephalogram monitoring in the critically ill.

Authors:  John J Wittman; Lawrence J Hirsch
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

3.  Inter-rater agreement on identification of electrographic seizures and periodic discharges in ICU EEG recordings.

Authors:  J J Halford; D Shiau; J A Desrochers; B J Kolls; B C Dean; C G Waters; N J Azar; K F Haas; E Kutluay; G U Martz; S R Sinha; R T Kern; K M Kelly; J C Sackellares; S M LaRoche
Journal:  Clin Neurophysiol       Date:  2014-11-20       Impact factor: 3.708

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.